基因疗法治疗遗传性心律失常症
Mara R Turkieltaub Paredes1,2, Mohit Hulsurkar1,2, Xander H T Wehrens3,4,5,6,7,8
1Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, 77030, USA.
Journal of cardiovascular translational research
|October 30, 2025
概括
基因疗法为遗传性心律失常提供了一个有希望的,潜在的治愈治疗方法,这是一种遗传性心律失常. 这种方法解决了传统治疗方法的局限性,并探索了针对布鲁加达综合征等疾病的基因传递进步.
科学领域:
- 心脏病学 心脏病学
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 遗传性心律失常是影响心脏电气系统的遗传性疾病.
- 这些疾病显著增加了由于遗传突变的死亡风险.
- 目前的治疗方法,如药物和手术,往往缺乏有效性,并导致并发症.
研究的目的:
- 审查遗传性心律失常的基因疗法应用.
- 分析基因传递方法来治疗这些心律障碍.
- 突出基因疗法的治疗潜力和挑战.
主要方法:
- 对针对特定遗传性心律失常的基因疗法最近的研究进行审查.
- 分析病毒和非病毒基因传递系统的进步.
- 对分子机制和候选基因的检查.
主要成果:
- 基因疗法正在成为一种可行且潜在的治疗方法.
- 分子机制的阐明和候选基因的识别正在推进.
- 基因传递方法的进步提高了治疗潜力.
结论:
- 基因疗法为传统治疗遗传性心律失常提供了一个可行的替代方案.
- 基因传递的进一步进展对于治疗成功至关重要.
- 本综述涵盖布鲁加达综合征,CPVT,LQTS,AF和ACM,评估基因治疗的作用.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Mechanism of Cardiac Arrhythmias
1.6K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.6K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
387
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
387
Gene Therapy
27.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.3K
Cardiomyopathy V: Interprofessional Care
326
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
326
Cardiomyopathy II: Dilated Cardiomyopathy
455
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
455


